Spero Therapeutics (NASDAQ:SPRO) Shares Pass Above 200-Day Moving Average - Should You Sell?

Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.03 and traded as high as $2.98. Spero Therapeutics shares last traded at $2.94, with a volume of 1,836,464 shares.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of Spero Therapeutics to a "hold" rating in a report on Saturday. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $5.00.

Spero Therapeutics Price Performance

The company has a market capitalization of $168.85 million, a P/E ratio of -2.36 and a beta of 1.31. The company has a 50 day moving average of $1.41 and a 200-day moving average of $1.05.

Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.25) EPS for the quarter, beating analysts' consensus estimates of ($0.55) by $0.30. The business had revenue of $5.87 million during the quarter, compared to analyst estimates of $11.00 million. Spero Therapeutics had a negative return on equity of 123.50% and a negative net margin of 156.48%. Research analysts predict that Spero Therapeutics, Inc. will post -1.2 EPS for the current fiscal year.

Institutional Trading of Spero Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Monimus Capital Management LP bought a new position in Spero Therapeutics in the 4th quarter worth $320,000. Virtu Financial LLC purchased a new position in shares of Spero Therapeutics during the fourth quarter valued at about $47,000. Prudential Financial Inc. bought a new position in Spero Therapeutics in the fourth quarter worth about $51,000. JPMorgan Chase & Co. raised its stake in Spero Therapeutics by 26,011.9% in the fourth quarter. JPMorgan Chase & Co. now owns 61,624 shares of the company's stock worth $63,000 after buying an additional 61,388 shares in the last quarter. Finally, ADAR1 Capital Management LLC lifted its holdings in Spero Therapeutics by 7.8% in the fourth quarter. ADAR1 Capital Management LLC now owns 801,277 shares of the company's stock worth $825,000 after buying an additional 57,818 shares during the period. Hedge funds and other institutional investors own 25.60% of the company's stock.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.